Phase I Study of Pharmacological and

Departments of Medicine [J. L, A. T. H.. W. D. B., C. J.. .... abbreviations used are: ..... ftn. QJ . ÖU. uÃœ 60 i. 40. 5 et. 20 • "' ââ...

0 downloads 0 Views 2MB Size

Recommend Documents

Stevens, S. J. Lee, D. A. Lowenthal, I. Haines, T. D. Walsh,. L. Baltzer ..... potential antitumor agents: a selective screening study. Cancer Treat. Rep.,. 62:45-74 ...

This communication reports the results obtained from a Phase I trial performed ...... Pisters, K. M. W., Tyson, L. B., Tong, W., Fleisher, M., Miller,. V. A., Grant, S. C. ...

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol. Cancer Ther. 2008;7(9):2955-66. 44.

Mar 15, 2008 - cycle of therapy was 805/ul and the median platelet nadir was 48,000/ul. Other toxic .... This was achieved using a Waters model 510 pump and ...

S. G. E., R. D., C. S., D. D. V. H., E. K. R.]; Brooke Army Medical. Center, Fort Sam ... 1 Supported in part by Ilex Oncology Inc., NIH Grant CA54174 to The.

was 6.9 /¿Mwith little interpatient variability seen. ... Phase I study of MP administered as a prolonged i.v. infusion. ... Three patients were treated at 2 different.

long-term venous access catheters has made prolonged infusion of vinblastine and ... 3The abbreviations used are: CVI, continuous vinblastine infusion; VLB«, steady-state serum ..... N. Engl. J. Med., 291: 127-133, 1974. 18. Ratain, M. J. ...

Mar 15, 2008 - nary function defined as a carbon monoxide diffusion capacity of at least 80% of predicted and a ... UV detection was accom plished using a ...

Jul 15, 1995 - Phase I Clinical and Pharmacological Study of Suppression of Human Antimouse. Antibody ... V. V., D. B., H. W., G. H.¡,Laboratory Medicine ¡H.F.], and Clinical Immunology and Biological Therapy [J. L M.],. The University of ....

cis-Diamminedichloroplatinum(II) in Patients with Advanced Cancer1. Richard L. ... Received 12/2/85; revised 3/14/86; accepted 4/28/86. The costs of .... ately centrifuged, and the plasma was decanted and frozen at —20°C until the time of ...

9-AC,3 9-nitrocamptothecin, topotecan, irinotecan, karenitecin, and DX-8951f ... of 12 weeks, adequate bone marrow reserve (defined as ab- solute neutrophil ...

ABSTRACT. Purpose: A Phase I study of exatecan, a new water- soluble camptothecin derivative, was conducted to deter- mine the maximum tolerated dose ...

Jan 15, 1994 - Phase I and Pharmacological Study of the Novel Topoisomerase I Inhibitor .... to the aqueous insolubility of the closed-ring CPT lactone (1-7). ... O2CH 3. SN-38. Fig. 1. Structures of CPT-11 and SN-38. To date, phase I and II trials o

control. Clinical Pharmacological Studies. The pharmacokinetic behavior of. IDR was examined using a HPLC method adapted from that of Peng. 2990. Research. ... Compounds were de tected by fluorescence, using excitation and emission wavelengths of. 47

Grant support: Access Pharmaceuticals, Inc., Dallas, TX. The costs of publication of this article were defrayed in part by the payment of page charges. This article ...

them, to break down all of the components of the ECM, includ- ing the basement membrane (1). ... novel synthetic hydroxamic acid derivative (Fig. 1) able to .... (free base). 1913 ..... We wish to thank Drs. T. S. Ganesan and N. Dobbs (Imperial.

At the 560 mg/m2/day dose level, the mean percentage of .... patients with advanced solid malignancies; (b) determine the ... gational agents in the previous 4 weeks; (g) no nitrosoureas or ... local reactions were not considered in altering the incr

Apr 15, 2018 - ... /£.K. K.. D. A. M, B. G. L., R. C. D.J and the Department of Radiologi' ¡E.K. ... 4-Ipomeanol (IPO), a naturally occurring pulmonary toxin, is the first cytotoxic ... principal toxicity of IPO administered as a 30-min infusion ev

(254-S; NSC 37510ID) Administered by 5-Day Continuous Intravenous ..... macodynamics was calculated by the method of simple least squares of .... crease in total plasma platinum concentration between the early and later stages of drug administration.

of CI-980,. A Novel. Synthetic. Antimicrotubule. Agent1. Eric. K. Rowinsky,2. G. Scott. Long,. Dennis ..... pelvis or spine or. 6 courses of chemotherapy containing an alkylating agent or 2 courses ... City,. CA), which were conditioned twice with. 2

4The abbreviations used are: VP-16, etoposide; Clr, plasma clearance, ('/„, .... The renal clearance of VP-16 (Cl,) was determined using the formula:.

Oncology. Research. [J. M. R.. M. M. A.. M. J. K.l. and. Cancer. Statistics. [J. A. S.] ... Oncology. Mayo. Clinic,. Scottsdale,. Arizona. 85259. [T. R. F.]. ABSTRACT .... I colon cancer. LX-l lung cancer, and. MX-l mammary carcinoma. In contrast to.

Joseph P. O'Connell,5 Linda D. Marks, Linda Williams, Fouad Farag, Charles W. Young, .... 10-EDAM was supplied by Ciba-Geigy, Basel, Switzerland. In the.

(Milford,. MA) as well as a Spectroflow. 980 programmable fluorescence detector. (Kratos. Division, ...... E. M., Pajak, T. F., and Bateman,. J. R. Adriamycin given.